Historic Partnership between the Weizmann Institute of Science and Institut Curie
25.3.2019 19:54:00 EET | Business Wire | Press release
On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics.
Collaborative research programs
This partnership will extend to many disciplines, including physics,
chemistry, cellular biology, epigenetics, genetics, immunology and
single cell approaches, imagery and data collection. The complementarity
of the research between the various groups at Institut Curie and at the
Weizmann Institute has been recognized in particular at the occasion of
joint scientific workshops held regularly alternatively in Paris and
Rehovot. Each research program will be organized around a pair of
researchers with a scientist from Institut Curie and a scientist from
the Weizmann Institute of Sciences, who will receive support on the
annual basis. This partnership also includes exchanges of scientists and
a Curie-Weizmann symposium organized every two years, with alternate
locations in Rehovot, Israel, and in Paris, which will be focused on one
of the subjects of research cooperation.
To finance the start of
this cooperation, Institut Curie and the Weizmann Institute of Sciences
will finance this research program for €200,000 each, and will organize
a joint fundraiser with philanthropists and corporate sponsors.
Projects with high hopes
There are numerous common interests
between the two Institutes. They can range from the description of
defects in cell nuclei to the mechanics of cell migration, or the
behavior of neural networks. A few examples of exciting ongoing projects
are highlighted below.
During his sabbatical visit at Institut
Curie in 2012, Professor Nir Gov (Weizmann Institute) participated in
several projects ranging from cell migration to collective cell
behaviors and neuron growth. For instance, he developed a theory in
collaboration with Raphael Voituriez (Sorbonne University), which
explains the observations of the team of Matthieu Piel (Institut Curie)
on the links between persistence and speed of migrating cells. This
theory gave rise to collaborative developments between these three teams
to predict important aspects of the migratory behavior of immune cells.
He
also collaborated with Pascal Silberzan at Institut Curie to understand
the behavior of cells packed at very high density on a surface. This
joint work combining experiments and theory, has highlighted the
importance of an intrinsic biological ageing of the cell population.
This project has helped understanding how cells can come to an arrest
while maintaining a capacity to respond to external perturbations such
as an injury.
Elisha Moses (Weizmann Institute) has a longstanding
interaction with the group of Professor Jean-Louis Viovy (Institut
Curie), now headed by Stéphanie Descroix, on the applications of
microfluidic devices to the study of living neuronal networks. He spent
three months in Paris, during which he and Dr. Catherine Villard of the
Descroix lab developed an optogenetic assay for guiding axonal growth.
This work has the potential for controlling growth of neurons and of
neuronal tumors within the brain. Drs. M. Vignes and R. Renault, two
talented researchers who were working on the project as students, have
now graduated and branched off into very interesting conceptual and
practical applications of this approach.
An important complementarity
The two institutions are both
highly complementary and display many mutually common attributes.
Institut
Curie is the premier research center in France conducting cancer
research, including all facets of carcinogenesis. Its research center
brings together 1,200 researchers working in 12 joint research units
organized in four areas based on natural scientific interactions and
robust medical potentiality. A strong advocate of international
cooperation , it welcomes more than 80 nationalities. Equipped with
advanced technology platforms, it is an important resource for
researchers around the world. Institut Curie is also a state-of-the-art
hospital complex that provides care and support for all cancer types and
welcomes more than 50,000 patients each year. It has developed
particularly innovative treatments directly from the work of its
research center. Institut Curie also trains students in science and
cancer research with the goal of increasing the knowledge about the
topic.
The Weizmann Institute of Science is among the ten premier
institutes of fundamental research in the world: 2,500 scientists work
on its campus in Rehovot in the complementary fields of mathematics and
computer science, physics, biology, chemistry, and biochemistry. The
Weizmann Institute of Science has a long history of research and
discoveries rooted in a mission of advancement of science for the
benefit of humanity; cancer research accounts for 40% of the total
budget of the Institute, which shapes and hosts a large part of the
leadership in Israel and contributes to the advancement and
understanding of scientific issues among all audiences.
Both
institutions have powerful means of technology transfer that leverage
the discoveries of their labs for the benefit of patients, whether
through the creation of medications, medical devices or other
technologies.
A shared vision of science
Science at the service of people
- this is the best way to describe the credo of the two institutes, both
of which were founded upon great personalities who have made an
important mark in the history of the world.
Chaim Weizmann, chemist
and author of many discoveries and publications, is the founder of the
Weizmann Institute, and was the first president of the State of Israel
between 1949 and 1952. Marie Curie, born Maria Sklodowska, founded the
Radium Institute in 1909. The first female professor and holder of a
chair position at the Sorbonne, the first woman to win two Nobel prizes
and be enshrined at the Pantheon in Paris on her own merit. In many
ways, these two scientists have had a remarkable journey.
But
beyond these prestigious founders, the two institutes share the same
vision of science, at the service of people and driven by strong values,
the same curiosity for discovery and knowledge at the service of human
health.
The
Weizmann Institute of Science and Institut Curie also share a common
belief that international collaborations in the field of institut-curie.org
science and the exchange of ideas across interdisciplinary boundaries
can accelerate progress to the benefit of humanity.
It is this
common ground which today enables this collaboration to take root and
which will tomorrow allow us to multiply efforts and as a result enjoy
major new discoveries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190325005638/en/
Contact information
Yohan Philippe
yohan.philippe@curie.fr
+33
(0)1 56 24 55 53
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
